文献速递肝病

奥贝胆酸对非酒精性脂肪性肝炎患者脂蛋白谱的影响

Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis.
PubMed 文献 · J Hepatol · 2019-10-18

本研究纳入FLINT试验中196例非酒精性脂肪性肝炎患者(奥贝胆酸组99例,安慰剂组97例),分析奥贝胆酸治疗72周及停药24周后脂蛋白亚组分变化。结果显示奥贝胆酸组12周时小VLDL、大/小LDL颗粒增加,HDL颗粒减少,停药24周后恢复至基线水平。

要点

  • 奥贝胆酸治疗12周升高总LDL颗粒浓度并增加小VLDL颗粒。
  • 奥贝胆酸治疗12周降低总HDL颗粒浓度,尤其大和中HDL颗粒。
  • 停药24周后脂蛋白颗粒浓度恢复至基线水平。

核心结论

  • 奥贝胆酸治疗12周与非酒精性脂肪性肝炎患者小VLDL颗粒、大和小LDL颗粒增加及HDL颗粒减少相关。
  • 停药24周后这些脂蛋白浓度恢复至基线值。

研究设计与样本

  • 研究纳入FLINT试验中196例非酒精性脂肪性肝炎患者,奥贝胆酸组99例,安慰剂组97例。
  • 在基线、随机后12周和72周以及治疗结束后24周评估VLDL、LDL和HDL颗粒。

主要发现

  • 奥贝胆酸组与安慰剂组12周时大VLDL颗粒浓度基线校正均值分别为6.8 vs. 8.9 nmol/L(p=0.002)。
  • 12周时小VLDL颗粒浓度分别为33.9 vs. 28.0 nmol/L(p=0.02)。
  • 12周时总LDL颗粒浓度分别为1,667 vs. 1,329 nmol/L(p<0.0001)。
  • 12周时大浮力LDL颗粒浓度分别为475 vs. 308 nmol/L(p≤0.001),小密LDL颗粒浓度分别为1,015 vs. 872 nmol/L(p=0.002)。
  • 奥贝胆酸组总HDL颗粒浓度降低,尤其大和中HDL颗粒,停药后恢复。

临床怎么用

  • 奥贝胆酸治疗期间需关注脂蛋白颗粒变化,尤其是LDL颗粒增加。
  • 停药后脂蛋白变化可逆,提示需权衡治疗获益与心血管风险。

局限性

  • 研究基于FLINT试验样本,样本量有限。
  • 未报告心血管事件结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Obeticholic acid (OCA), a farnesoid X receptor agonist, increases total and low-density lipoprotein cholesterol (LDL-C) in patients with non-alcoholic steatohepatitis. In the present study, we aimed to evaluate the impact of OCA therapy on lipoprotein sub-particles. METHOD: This study included 196 patients (99 OCA group and 97 placebo group) who were enrolled in the FLINT trial and had samples available for lipid analysis and liver biopsies at enrollment and end-of-treatment (EOT) at 72 weeks. Very low-density lipoprotein (VLDL), low-density lipoprotein (LDL), and high-density lipoprotein (HDL) particles were evaluated at baseline, 12 and 72 weeks after randomization, and 24 weeks following EOT. RESULTS: Baseline lipoprotein profiles were similar among OCA and placebo groups. OCA did not affect total VLDL particle concentrations, but OCA vs. placebo treatment was associated with decreased large VLDL particle concentration at 12 weeks (baseline-adjusted mean: 6.8 vs. 8.9 nmol/L; p = 0.002), mirrored by an increase in less atherogenic, small VLDL particle concentration (33.9 vs. 28.0 nmol/L; p = 0.02). After 12 weeks, total LDL particle concentration was higher in the OCA group than the placebo group (1,667 vs. 1,329 nmol/L; p <0.0001), characterized by corresponding increases in both less atherogenic, large-buoyant LDL (475 vs. 308 nmol/L; p ≤0.001) and more atherogenic small-dense LDL particles (1,015 vs. 872 nmol/L; p = 0.002). The changes in LDL particle concentrations were similar between treatment groups (OCA and placebo) 24 weeks following EOT due to improvement in the OCA cohort. Compared to placebo, a reduction in total HDL particle concentration, particularly large and medium HDL particles, was noted in the OCA-treated patients, but this resolved after drug discontinuation. CONCLUSION: OCA therapy is associated with increases in small VLDL particles, large and small LDL particles, and a reduction in HDL particles at 12 weeks. These lipoprotein concentrations reverted to baseline values 24 weeks after drug discontinuation. LAY SUMMARY: Non-alcoholic steatohepatitis is a chronic liver disease that is associated with an increased risk of developing cirrhosis and cardiovascular disease. Recently, obeticholic acid (OCA), a farnesoid X receptor agonist, improved liver disease but led to an increase in cholesterol. However, the impact of OCA on cholesterol is not well understood. In the present study, we show that OCA therapy is associated with a detrimental increase in lipoprotein levels, which improves after drug discontinuation. ClinicalTrials.gov numbers: NCT01265498.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Siddiqui MS, Van Natta ML, Connelly MA, et al. Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis. J Hepatol. 2019. PMID: 31634532. doi:10.1016/j.jhep.2019.10.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。